[{"id":"c72f3a57-80b1-4204-bf22-b374de81ba27","acronym":"","url":"https://clinicaltrials.gov/study/NCT07114653","created_at":"2025-08-16T14:08:30.041Z","updated_at":"2025-08-16T14:08:30.041Z","phase":"","brief_title":"The Role of POLE Mutation in High Risk Endometrial Cancer.","source_id_and_acronym":"NCT07114653","lead_sponsor":"Far Eastern Memorial Hospital","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-08-11"},{"id":"0cde78dd-3c84-4aec-a573-c0c0e01915a1","acronym":"OPTEC","url":"https://clinicaltrials.gov/study/NCT03460483","created_at":"2021-01-18T17:03:29.688Z","updated_at":"2025-02-25T13:48:28.789Z","phase":"","brief_title":"Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care","source_id_and_acronym":"NCT03460483 - OPTEC","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1001","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-20"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"dc334b0f-8b5c-4b2f-8468-f243cf63a6a0","acronym":"NCI-2022-09458","url":"https://clinicaltrials.gov/study/NCT05627635","created_at":"2022-11-25T15:58:22.182Z","updated_at":"2025-02-25T15:20:07.740Z","phase":"Phase 1/2","brief_title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05627635 - NCI-2022-09458","lead_sponsor":"City of Hope Medical Center","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2025-02-12"},{"id":"256df84b-62ee-44dd-bf61-7e052e3333ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02899793","created_at":"2021-01-18T14:13:54.458Z","updated_at":"2025-02-25T16:05:12.956Z","phase":"Phase 2","brief_title":"Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer","source_id_and_acronym":"NCT02899793","lead_sponsor":"Yale University","biomarkers":" MSI • POLE • POLD1","pipe":" | ","alterations":" POLE mutation • POLD1 mutation","tags":["MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-31"},{"id":"36e9c4c3-28f9-471f-91db-41aa4b6178a4","acronym":"RAINBO","url":"https://clinicaltrials.gov/study/NCT05255653","created_at":"2022-02-24T13:52:52.644Z","updated_at":"2025-02-25T15:00:17.741Z","phase":"Phase 2/3","brief_title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","source_id_and_acronym":"NCT05255653 - RAINBO","lead_sponsor":"Leiden University Medical Center","biomarkers":" ER • POLE","pipe":" | ","alterations":" ER positive • MSI-H/dMMR • POLE mutation","tags":["ER • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone"],"overall_status":"Recruiting","enrollment":" Enrollment 1615","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-11-28"},{"id":"52596305-5825-4a69-9da4-f4d1348c8313","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774419","created_at":"2021-03-01T14:52:30.559Z","updated_at":"2025-02-25T13:19:57.496Z","phase":"Phase 2","brief_title":"Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery","source_id_and_acronym":"NCT04774419","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-11-11"},{"id":"c67606ea-7796-46a1-9d35-f3d0edacc3ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912572","created_at":"2021-01-18T14:17:54.432Z","updated_at":"2024-07-02T16:35:08.730Z","phase":"Phase 2","brief_title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02912572","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation • MSH6 expression","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-19"},{"id":"9c246bac-2a05-4be1-9b1f-a7e2e819e603","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT03012581","created_at":"2021-01-17T17:45:03.399Z","updated_at":"2025-02-25T14:37:06.018Z","phase":"Phase 2","brief_title":"Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012581 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 269","initiation":"Initiation: 06/16/2017","start_date":" 06/16/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 11/11/2023","study_completion_date":" 11/11/2023","last_update_posted":"2024-02-28"},{"id":"b53740c4-b1e7-41cb-af68-382331f382df","acronym":"","url":"https://clinicaltrials.gov/study/NCT06206083","created_at":"2024-01-16T20:20:19.657Z","updated_at":"2025-02-25T13:13:33.863Z","phase":"","brief_title":"Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis","source_id_and_acronym":"NCT06206083","lead_sponsor":"National Institute of Cancerología","biomarkers":" TP53 • MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" POLE mutation","tags":["TP53 • MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-02-28"},{"id":"ebea8369-a309-4f15-9f25-3c7393207af5","acronym":"PRODIGYN","url":"https://clinicaltrials.gov/study/NCT05855941","created_at":"2023-05-12T17:04:42.348Z","updated_at":"2024-07-02T16:35:40.129Z","phase":"","brief_title":"Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)","source_id_and_acronym":"NCT05855941 - PRODIGYN","lead_sponsor":"Region Västerbotten","biomarkers":" POLE • BRCA • CD31 • PECAM1","pipe":" | ","alterations":" POLE mutation • BRCA mutation","tags":["POLE • BRCA • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 05/01/2032","primary_completion_date":" 05/01/2032","study_txt":" Completion: 05/01/2032","study_completion_date":" 05/01/2032","last_update_posted":"2023-08-14"},{"id":"68de479e-5dac-4d68-806e-b6cfb11e2fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05793333","created_at":"2023-03-31T15:02:54.769Z","updated_at":"2024-07-02T16:35:41.614Z","phase":"","brief_title":"Predictors of Node Positivity in Endometrial Cancer","source_id_and_acronym":"NCT05793333","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53 • MSI • POLE","pipe":" | ","alterations":" TP53 mutation • MSI-H/dMMR • POLE mutation","tags":["TP53 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MSI-H/dMMR • POLE mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-07-28"},{"id":"44b18821-ce38-48ad-a230-792c3c2069f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03810339","created_at":"2021-01-18T18:49:40.399Z","updated_at":"2024-07-02T16:35:44.660Z","phase":"Phase 2","brief_title":"Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors","source_id_and_acronym":"NCT03810339","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • MSI • POLE • POLD1","pipe":" | ","alterations":" POLE mutation • POLD1 mutation","tags":["PD-L1 • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 01/15/2024","study_completion_date":" 01/15/2024","last_update_posted":"2023-06-27"},{"id":"ff116e80-4e73-4e53-9069-5abc8dcbf0d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05707312","created_at":"2023-01-31T15:00:00.151Z","updated_at":"2024-07-02T16:35:56.723Z","phase":"","brief_title":"Staging Endometrial caNcer Based on molEcular ClAssification","source_id_and_acronym":"NCT05707312","lead_sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1032","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-01-31"},{"id":"567321d4-4a84-454e-b1af-fa8b176e2bd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03435107","created_at":"2021-01-18T16:56:37.645Z","updated_at":"2024-07-02T16:35:58.946Z","phase":"Phase 2","brief_title":"Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03435107","lead_sponsor":"Asan Medical Center","biomarkers":" POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation","tags":["POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oxaliplatin • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 04/12/2018","start_date":" 04/12/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-12-19"},{"id":"0a61150d-21b5-45c1-826c-99d62c159626","acronym":"","url":"https://clinicaltrials.gov/study/NCT03491345","created_at":"2021-01-18T17:11:42.816Z","updated_at":"2025-02-25T16:07:47.926Z","phase":"Phase 2","brief_title":"K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor","source_id_and_acronym":"NCT03491345","lead_sponsor":"Yonsei University","biomarkers":" PD-L1 • MSI • POLE • POLD1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • POLE mutation • POLD1 mutation","tags":["PD-L1 • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • POLE mutation • POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/01/2017","start_date":" 08/01/2017","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-08-09"},{"id":"72de5b40-499b-488c-91b2-17d19fd2167c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03150706","created_at":"2021-01-18T15:31:46.427Z","updated_at":"2025-02-25T16:06:14.721Z","phase":"Phase 2","brief_title":"Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03150706","lead_sponsor":"Asan Medical Center","biomarkers":" POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation","tags":["POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 33","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-04-03"}]